Rhizen drug secures approval in the USA The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered…martin02.10.2021
Novaremed secures US$50 million Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to…martin02.03.2021
Axtria driving growth from Basel The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry…martin02.01.2021
Technologiepark Basel celebrates its role as a driver of innovation The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and…martin01.28.2021
Basel Area has ever more to offer investors The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than…martin01.28.2021
Basel researchers developing universal cancer therapy Researchers from Basel are working on the development of a therapy in which pre-prepared immune cells can be used to…martin01.26.2021
Opterion Health AG moving to Muttenz Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from…martin01.22.2021
Evolva brings natural sugar blocker to market The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be…martin01.21.2021
Holmusk opens new office in Basel Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis.…martin01.18.2021
Zifo RnD Solutions coming to Basel Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo…martin01.04.2021